CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 27, 2013, Pages 11091-11096

  Loi, Sherene ^a   Pommey, Sandra ^b   Haibe Kains, Benjamin ^c   Beavis, Paul A ^a   Darcy, Phillip K ^a,d   Smyth, Mark J ^a,d,e,f   Stagg, John ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Institut du Cancer de Montreal   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Ectonucleotidase; Immunogenic cell death; Immunotherapy

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5' NUCLEOTIDASE; ADENOSINE A2A RECEPTOR; ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD73; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; MAJOR CLINICAL STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

ECTONUCLEOTIDASE; IMMUNOGENIC CELL DEATH; IMMUNOTHERAPY;

5'-NUCLEOTIDASE; ADAPTIVE IMMUNITY; ANIMALS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GPI-LINKED PROTEINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, SCID; PROGNOSIS;

MUS;

EID: 84879705407     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1222251110     Document Type: Article

References (30)

1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938-1948.
2. Carey LA, et al. (2012) TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30(21):2615-2623.
3. Irshad S, Ellis P, Tutt A (2011) Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr Opin Oncol 23(6):566-577.
4. Carey LA (2011) Directed therapy of subtypes of triple-negative breast cancer. Oncologist 16(Suppl 1):71-78.
5. Metzger-Filho O, et al. (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15):1879-1887.
6. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 11(3):215-233.
7. Mattarollo SR, et al. (2011) Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 71(14):4809-4820.
8. Michaud M, et al. (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334(6062):1573-1577.
9. Ma Y, et al. (2011) Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208(3):491-503.
10. Ghiringhelli F, et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. NatMed 15(10):1170-1178.
11. West NR, et al. (2011) Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13(6):R126.
12. Beavis PA, Stagg J, Darcy PK, Smyth MJ (2012) CD73: A potent suppressor of antitumor immune responses. Trends Immunol 33(5):231-237.
13. Stagg J, Smyth MJ (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29(39):5346-5358.
14. Ohta A, et al. (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 103(35):13132-13137. (Pubitemid 44338928)
15. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. Nature 414(6866):916-920. (Pubitemid 34024743)
16. Bavaresco L, et al. (2008) The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem 319(1-2):61-68.
17. Sadej R, Spychala J, Skladanowski AC (2006) Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res 16(3):213-222. (Pubitemid 44085095)
18. Serra S, et al. (2011) CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118(23):6141-6152.
19. Spychala J, et al. (2004) Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer. Clin Cancer Res 10(2):708-717. (Pubitemid 38174010)
20. Stagg J, et al. (2012) CD73-deficient mice are resistant to carcinogenesis. Cancer Res 72(9):2190-2196.
21. Stagg J, et al. (2011) CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71(8):2892-2900.
22. Stagg J, et al. (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 107(4):1547-1552.
23. Wang L, et al. (2011) CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 121(6):2371-2382.
24. Yegutkin GG, et al. (2011) Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 41(5):1231-1241.
25. Haibe-Kains B, et al. (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 104(4):311-325.
26. Desmedt C, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14(16):5158-5165.
27. Desmedt C, et al. (2011) Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 29(12):1578-1586.
28. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001(30):96-102.
29. Kershaw MH, et al. (2004) Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 173(3):2143-2150. (Pubitemid 38971653)
30. Lo Nigro C, et al. (2012) NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 107(1):75-83.